Sort   by:  
 Page size 
TranscriptomicsAntibody mRNA-seq repertoire sequencing to study relapses after B-cell depletion therapy
Rituximab (RTX) is widely used as a first-line therapeutic strategy for patients affected by immune thrombocytopenia (ITP). However, a large proportion of patients relapse after successful treatment. The present NGS assay was done to help find the cause for this relapse on the immune repertoire leve...
ORGANISM(S): Homo sapiens 
2021-01-18 | E-MTAB-9953 | biostudies-arrayexpress
TranscriptomicsBAFF and CD4+ T cells are major survival factors for long-lived splenic plasma cells in a B-cell–depletion context
Previous data have suggested that B-cell–depletion therapy may induce the settlement of autoreactive long-lived plasma cells (LLPCs) in the spleen of patients with autoimmune cytopenia. To investigate this process, we used the AID-CreERT2-EYFP mouse model to follow PCs engaged in an immune response....
ORGANISM(S): Mus musculus 
2018-02-19 | E-MTAB-6449 | biostudies-arrayexpress
Transcriptomicssingle cell RNAseq of memory B cells in the context of rituximab-treated ITP patients
Rituximab (RTX) is widely used as a first-line therapeutic strategy in B cell-mediated autoimmune diseases. However, a large proportion of patients either do not respond to the treatment or relapse during B cell reconstitution. Primary immune thrombocytopenia (ITP) is a prototypic B cell mediated au...
ORGANISM(S): Homo sapiens 
2021-01-31 | E-MTAB-9955 | biostudies-arrayexpress
Sort   by:  
 Page size